Hyderabad, Jun 9 : Indian Institute of Chemical Technology, (IICT), a constituent laboratory of CSIR and Lee Pharma Limited, an integrated pharmaceutical company, based in Hyderabad have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG).
Recently, 2-DG developed by DRDO and Dr Reddy’s Laboratories has received approval for use in Covid-19 patients.
It has been found to help speed up recovery and reduce oxygen dependence and Dr Reddy’s Laboratories has launched the drug in the form of sachets, a release said on Wednesday.
Lee Pharma informed that they would file the application for getting the approval from DCGI, New Delhi and it will manufacture and commercialize the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam in Andhra Pradesh, which has the accreditations, by global regulatory agencies.
Dr Srivari Chandrashekar, Director CSIR-IICT highlighted that, “ There is a role of CSIR in development of 2-DG, as CSIR-CCMB tested the drug on SARS-CoV-2 viral cultures.
CSIR has been engaged in development of drugs for treatment of Covid-19 and has undertaken many clinical trials for repurposed drugs. Additionally, this agreement with Lee Pharma Limited is towards increasing affordable therapeutic options for treatment of Covid-19”.
Raghumitra Alla, Director, Lee Pharma said, “This collaboration with CSIR-IICT for 2-DG API is part of our broader strategy for enhancing Covid-19 treatment options.
Further CSIR-IICT, Hyderabad is well-known for its high quality research & development of various new molecules and we feel proud to be associated with them,” he added.(UNI)